Similarly, Liu et al. observed higher TPEX cell levels and lower terminally exhausted T-cell levels in NSCLC responders compared to non-responders following anti-PD-1 therapy, reinforcing the potential of TPEX cells as biomarkers [112]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.